Immutep (IMM.AX) Aktie Kurs
Immutep Kurs
De seneste 19 år voksede Immuteps omsætning med 102,0 % årligt og nåede 14,56 Mio. AUD. For Immutep er nettoavance på -544,8 % op i forhold til -18.906,5 % for et par år siden.
Immutep aktiekurs
Hent disse data via Eulerpool API
100.000 requests/md. gratis · intet kreditkort
Immutep aktie og aktieanalyse
Hyppigt stillede spørgsmål om Immutep-aktien
The business model of Immutep Ltd revolves around developing and commercializing immunotherapy treatments. Immutep Ltd focuses on the development of LAG-3 related products, which play a crucial role in regulating the immune system. By leveraging its expertise and technology, the company aims to treat a wide range of diseases, including cancer and autoimmune disorders. Immutep Ltd collaborates with various partners and conducts clinical trials to evaluate the safety and effectiveness of its therapies. Through strategic partnerships and licensing agreements, the company aims to bring its innovative treatments to market, ultimately improving patient outcomes and advancing the field of immunotherapy.
Immutep Ltd is primarily active in the biotechnology and healthcare industries.
The main competitors of Immutep Ltd in the market include companies like Bristol-Myers Squibb, AstraZeneca, Merck, Roche, and Novartis. These companies also operate in the biopharmaceutical sector and focus on developing innovative treatments and therapies. Immutep Ltd differentiates itself through its unique therapeutic pipeline and commitment to the development of immunotherapies. With their focus on immunomodulation and immuno-oncology, Immutep Ltd aims to make a significant impact in the field of cancer treatment and autoimmune diseases, setting itself apart from its competitors.
Immutep Ltd is an Australian biotechnology company specializing in developing immunotherapy treatments for cancer and autoimmune diseases. Established in 2001, Immutep has a rich history of pioneering research and significant advancements in the field of immune-based therapies. The company's extensive expertise lies in the development of its lead product candidate, eftilagimod alpha (efti), a soluble LAG-3 protein aimed at enhancing immune responses. Immutep Ltd has collaborated with renowned pharmaceutical companies and research institutions worldwide, reinforcing its dedication to advancing immunotherapy and ultimately improving patient outcomes. With a strong focus on innovation, Immutep continues to make significant contributions in the immunotherapy space, propelling the fight against cancer and autoimmune diseases forward.
Immutep Ltd, a leading biotechnology company, has achieved several significant milestones. Firstly, the company successfully completed a Phase IIb clinical trial for its flagship product, Eftilagimod Alpha (efti). The trial demonstrated promising results in treating metastatic breast cancer. Secondly, Immutep entered into a strategic collaboration with major pharmaceutical companies to further develop and commercialize efti. This collaboration enhances its growth potential and market reach. Additionally, Immutep received Fast Track designation from the U.S. FDA for efti, expediting its regulatory process. These accomplishments showcase Immutep Ltd's dedication to advancing breakthrough immunotherapies and solidify its position in the biotech industry.
Immutep Ltd is primarily present in several countries and regions worldwide. These include Australia, where the company is headquartered, as well as the United States, Europe, and Asia-Pacific. With a focus on developing novel immunotherapy treatments, Immutep Ltd has established a global presence to reach patients and collaborate with healthcare and bio-pharmaceutical partners across these regions.
Immutep Ltd is a leading biotechnology company that focuses on developing novel immunotherapeutic treatments. The company is dedicated to improving the lives of patients with cancer and autoimmune diseases through innovative research and development. Immutep's core values revolve around scientific excellence, integrity, and patient-centricity. With a commitment to advancing cutting-edge therapies, Immutep embraces a corporate philosophy centered on collaboration, innovation, and delivering breakthrough solutions. By harnessing the power of the immune system, Immutep aims to revolutionize the way diseases are treated, offering hope and improved outcomes to patients worldwide.
10 analytikere vurderer i øjeblikket Immutep-aktien: 9 anbefaler køb, 1 hold og 0 salg.
Omregnet til den aktuelle valutakurs handles Immutep-aktien til 0,01 EUR (0,02 AUD).
Immutep-aktien (IMM.AX) er noteret på 4 børser, herunder: ASX (IMM.AX), Frankfurt (YP1B.F), München (YP1B.MU).
Immutep Ltd is an Australian biotechnology company specializing in the development of immunotherapies for the treatment of cancer and autoimmune diseases. The company has two main product platforms, the Lymphocyte Activation Gene (LAG)-3 platform and the IMP321 platform. Its leading products are IMP321, an agonistic LAG-3 antibody, and eftilagimod alpha, an IMP321-based immunotherapy. Immutep also offers services for preclinical and clinical development of immunotherapies. The company has partnerships with pharmaceutical companies such as Novartis, GlaxoSmithKline, and Eddingpharm. It has a portfolio of patents and intellectual property in the LAG-3 and IMP321 areas, and has licensed its LAG-3 technology for predictive diagnostics in cancer patients. Overall, Immutep aims to research, develop, and market immunotherapies for the treatment of cancer and autoimmune diseases, as well as provide services for their development. It positions itself as a leading provider of immunotherapies based on LAG-3 and IMP321 technologies. Immutep Ltd is an Australian biotechnology company specializing in the development of immunotherapies for the treatment of cancer and autoimmune diseases. It has two main product platforms, LAG-3 and IMP321. Leading products include IMP321 and eftilagimod alpha. The company also offers services for preclinical and clinical development of immunotherapies. It has partnerships with Novartis, GlaxoSmithKline, and Eddingpharm. Immutep has patents and intellectual property in the LAG-3 and IMP321 areas. It has licensed its LAG-3 technology for predictive diagnostics in cancer patients. Overall, Immutep aims to research, develop, and market immunotherapies for cancer and autoimmune diseases, as well as provide development services. It positions itself as a leading provider of immunotherapies based on LAG-3 and IMP321 technologies.
-omsætningen for Immutep er 14,56 Mio. AUD. Dette tal er baseret på aktuelle finansielle data og afspejler virksomhedens forretningsydeevne.
-overskuddet for Immutep er -79,30 Mio. AUD. Nettooverskuddet afspejler virksomhedens rentabilitet efter fradrag af alle udgifter.
Pris-til-indtjening-forholdet (P/E) for Immutep er i øjeblikket -0,43. P/E-forholdet sammenligner den nuværende aktiekurs med indtjeningen pr. aktie og hjælper investorer med at vurdere værdiansættelsen af Immutep-aktien.
Pris-til-salgs-forholdet (P/S) for Immutep er i øjeblikket 2,33. P/S-forholdet sammenligner markedskapitalisering med årlig omsætning og fungerer som en værdiansættelsesmetrik for Immutep-aktien.
AlleAktien-kvalitetsscore for Immutep er 5/10.
ISIN for Immutep er AU000000IMM6. ISIN (International Securities Identification Number) er en globalt unik identifikator for værdipapirer.
WKN for Immutep er A2H81H. WKN (Wertpapierkennnummer) er et seks-cifret tysk identifikationsnummer for værdipapirer.
Tickeren for Immutep er IMM.AX. Tickersymbolet bruges til at handle Immutep-aktier på børsen.
Immutep aktie
Immutep Peer Group
Immutep Ticker
Immutep FIGI
Alle fundamentale data om Immutep i deep dive
Vores aktieanalyse af Immutep-aktien indeholder vigtige finansielle nøgletal som omsætning, profit, P/E-ratioen, P/S-ratioen, EBIT samt informationer om udbytte. Desuden ser vi på aspekter som aktier, markedskapitalisering, gæld, egenkapital og forpligtelser hos Immutep. Hvis du søger mere detaljerede oplysninger om disse emner, tilbyder vi på vores undersider omfattende analyser: